Lege Artis Medicinae

[Rituximab therapy in idiopathic inflammatory myopathies]

BODOKI Levente, VINCZE Melinda, GRIGER Zoltán, CSONKA Tamás, CSERI Karolina, HORTOBÁGYI Tibor, DANKÓ Katalin

JANUARY 20, 2013

Lege Artis Medicinae - 2013;23(01)

[Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by symmetrical weakness of proximal limb muscles. In the everyday practice it is not easy to treat idiopathic inflammatory myopathies. First-line therapy is based on corticosteroids. If there is no improvement in the symptoms and complaints in two months, a new immunosuppressant therapy has to be initiated. The aim of this summary is to present the biological agent rituximab in the therapy of this condition.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The Princess of Pain – Jacquelin du Pré ]

KÖVES Péter

Lege Artis Medicinae

[Result of 2012 - Q-SYMBIO and KiSel-10]

LIPTÁK Judit

Lege Artis Medicinae

[Weyer and the Crazy Witches ]

MAGYAR László András

Lege Artis Medicinae

[ORIGIN (Outcome Reduction with Initial Glargine INtervention)]

MATOS Lajos

Lege Artis Medicinae

[Fifty years of the Hungarian congenital abnormality registry and some important results]

MÉTNEKI Júlia, BÉRES Judit, CZEIZEL Endre

[The Hungarian Congenital Abnormality Registry (HCAR) was established in 1962 after the greatest tragedy of human teratology, the thalidomide-Contergan catastrophe. As far as we know HCAR was the first national-based registry in the world based on the mandatory notification of patients with different structural birth defects, i.e. congenital abnormalities (CAs) by medical doctors. The main task of the HCAR has been to determine as reliably as possible the baseline occurrence of different CAs. In addition three other secondary missions of the HCAR were defined: 1) to detect temporal and/or spatial increases (“clusters”) of CA and to evaluate the permanent changing trends of CAs; 2) to help plan medical and social services for cases with different CA; and 3) to estimate the public health importance of different CAs so that resources can be properly allocated. Here some important results of HCAR between 1962 and 2011, i.e. during 50 years are reported.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Rituximab therapy in rheumatoid arthritis]

SÜTŐ Gábor

[Rheumatoid arthritis is a chronic, lifelong disease that causes severe joint deformity, reduces quality of life, and, if not treated appopriately, leads to disability and substantial premature mortality. Its treatment is a multistep procedure, where different grades of treatment options follow each other. Besides traditional, diseasemodifying antirheumatic drugs (DMARDs) and biological therapies inhibiting TNF, a new therapautic option is the use of a chimeric antibody, rituximab, which inhibits B lymphocyte function. This drug is an effective and safe choice for those patients who have received various anti- TNF therapies or do not tolerate TNF inhibition.]

Hypertension and nephrology

[Systemic ANCA-associated vasculitis. Induction immunosuppression therapy, complications and outcome. Part 2]

HARIS Ágnes, POLNER Kálmán

[The present review is compiled of two parts, the first part aims to summarize the induction immunosuppressive therapy, the second part delineates the outcome and complications of ANCA-associated vasculitis. ANCA-associated vasculitis is a systemic disease, accompanied with rapidly progressive glomerulonephritis and severe, often life-threatening extrarenal complications. By early diagnosis and immediate initiation of immunosuppressive therapy both patient and renal outcome have been substantially improved. The major aims of modern therapeutic protocols are, besides improving survival, to decrease immunosuppressive drug toxicity and avoid infections. Immunosuppression is based on the combination of large dose of corticosteroid and cyclophosphamide, which is advisable to supplement by plasma exchange. The B-cell depleting anti-CD20 monoclonal antibody rituximab, which has already been available in Hungary, has been proved to be similarly effective in newly diagnosed ANCA-vasculitis, and even more effective in a relapsing disease, compared to cyclophosphamide. Amongst rituximab’s further indications in this disease is the preservation of young women’s fertility, and it also has priority in some other special cases. Early diagnosis and prompt immunosuppressive treatment have resulted that ANCAvasculitis became a treatable disease with reasonably good clinical outcome, yet both the disease and the immunosuppressive medications frequently cause complications, which necessitate continuous alertness of the attending nephrologists.]

Hungarian Immunology

[First experience with rituximab treatment in rheumatoid artritis: a case report of a multiresistant patient]

SIMKOVICS Enikő, BESENYEI Tímea, SZABÓ Zoltán, SZENTPÉTERY Ágnes, SZODORAY Péter, SZŰCS Gabriella, SZÁNTÓ Sándor, SZEKANECZ Zoltán

[INTRODUCTION - Here we describe the case of the first Hungarian rheumatoid arthritis (RA) patient treated with RTX. CASE REPORT - This multiresistant patient had received numerous immunosuppressive drugs and all three anti-TNF agents had been tried. These biologicals had to be stopped due to inefficacy or side effects. RTX treatment resulted in some subjective clinical improvement, as well as a decrease in rheumatoid factor and anti-CCP production. Clinical activity assessed by DAS28 fell after 18 weeks. B cells disappeared from the circulation, however, the percentage of activated T cells increased. We observed initial B cell recovery after 18 weeks. CONCLUSION - Clinical studies suggest that RTX is more effective right after the failure of the first TNF inhibitor. Efficacy of RTX in this patient suggests that this drug may also be effective in a multiresistant patient, who had tried numerous TNF blockers.]

Hypertension and nephrology

[Hypertensive and cardiovascular risks of nonsteroidal antiinflammatory drugs]

FARSANG Csaba, BEDROS J. Róbert, ALFÖLDI Sándor

[Nonsteroidal antiinflammatory drugs (NSAIDs) are among the most frequently used medicines. During the last ten years several original publications, reviews and meta-analyses were published on the cardiovascular safety of NSAIDs and the results underlined their potentially harmful cardiovascular side effects. It can also be emphasized that there are substantial differences between different compounds, and the CV risk does not depend on the ratio of COX-1/COX-2 selectivity. Cardiovascular risk can be increased by all NSAIDs and paracetamol with the possible exception of naproxen and probably aceclofenac.]

Lege Artis Medicinae

[DIFFUSE LARGE B-CELL NON-HODGKIN LYMPHOMA OF UNUSUAL LOCALISATION]

RESS Zsuzsa, ILLÉS Árpád, MATOLCSY András, TANYI Miklós, SZÖVÖRDI Éva, GERGELY Lajos

[INTRODUCTION - Diffuse large B-cell lymphoma frequently has bone involvement, but primary bone lymphoma is rare (around 4% of primary extranodal lymphomas). Long bones are most often affected, followed in frequency by the ribs, vertebrae, and pelvic bones. The main symptom is bone pain. CASE REPORT - The case of a young man is presented whose disease started with lumboischialgia. Since rheumatological treatment did not relieve the symptoms, MRI was performed, which showed a tumour with massive iliac bone destruction. Three months after the initial symptoms a surgical biopsy from the right ilium showed diffuse large B-cell lymphoma. Soon after acute renal insufficiency developed and the patient was put on haemodialysis. Based on the findings the disease was staged as Ann Arbor IV/B (bone and kidney), ECOG PS 3, International Prognostic Index 4. On the basis of the preliminary histological findings, reduced-dose CHOP chemotherapy was given, which resulted in a significant improvement of the renal function and haemodialysis could be abandoned. This was followed by 6 additional cycles of Rituximab-CHOP treatment and further 2 cycles of Rituximab-DHAP salvage chemotherapy with intrathecal prophylaxis, and, finally, since no response could be detected, R-IVAC treatment was given. After an initial response, the disease became progressive, and the patient died 9 months after the diagnosis was made from a disseminated chemoresistant disease. Autopsy confirmed extensive infiltration of the right iliac bone, kidneys, bone marrow, spleen, supraclavicular and abdominal lymph nodes, pancreas, scalp and brain. CONCLUSIONS - This case was chosen to be presented because of the unusual localisation of the diffuse large B-cell lymphoma, the initial diagnostic difficulty, and the very rapid progression despite the application of several aggressive chemotherapy schemes. A primary bone large B-cell lymphoma represents a diagnostic challenge with its rheumatological symptoms thus delaying diagnosis.]